Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir versus tenofovir alafenamide in hospitalized patients with COVID-19
IRCT20150808023559N23Phase 2Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir with Tenofovir alafenamide (2 arms). Primary endpoints: Mortality and Length of stay in hospital. Started Sep 2020; status: completed.
02
Drugs
favipiravirtenofovir alafenamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150808023559N23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150808023559N23.